N/A Completed N=103 Randomized Double-blind Treatment

Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal Study

Parkinson's Disease

Source: ClinicalTrials.gov NCT03998462 ↗

Enrolled (actual)

103

Serious AEs

0.0%

Results posted

Nov 2025

Primary outcomePrimary: Parkinson's Disease Questionnaire-39 — -1.03; -3.04 change score — p=0.34

Summary

To investigate the efficacy of Mindfulness-based Stress Reduction (MBSR) to improve quality of life, cognition, and mood, as well as to determine the longevity of the treatment response in individuals with Parkinson's disease (PD).

Outcome Measures

Outcome	Result	p-value
PRIMARY Parkinson's Disease Questionnaire-39	-1.03; -3.04	0.34
SECONDARY Matrix Reasoning Test	0.154; 1.04	0.41
SECONDARY State-Trait Anxiety Inventory	-1.40; -1.84	0.71

Eligibility Criteria

Inclusion Criteria

Clinical diagnosis of PD based on UK Brain Bank Criteria
40 years of age or older

Exclusion Criteria

Secondary causes of Parkinsonism (e.g. corticobasal degeneration, progressive supranuclear palsy, drug-induced parkinsonism)
Other neurological conditions (e.g. stroke)
Clinical diagnosis of dementia based on any previous neuropsychological testing
Psychosis, antipsychotic treatment or treatment for substance abuse
Uncorrected vision or hearing to adequately participate in the intervention
Prior formal training in MBSR or regular current MBSR practice
Inability to use a computer or technology for participation
Active/current suicidal ideation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03998462). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.